Trial results

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

NCT07684144 on ClinicalTrials.gov · last registry update 2026-09-03

An unusually large phase 3: 950 participants, more than double the 424 typical for the stage. Due to report 26 December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Percent Change in Body Weight from Baseline of the Parent Trial (20210184). Sponsors move these dates routinely; any movement since this site started watching is listed below. maridebart cafraglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

RECRUITING

Phase

P3

Drug

maridebart cafraglutide

Sponsor

Amgen

Sponsor type

Industry

Enrollment

950

Started

2026-07-29

Primary completion

2027-12-26 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Percent Change in Body Weight from Baseline of the Parent Trial (20210184)

Conditions studied

Obesity · Overweight · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the maridebart cafraglutide page for this molecule’s full trial and approval history.